Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia

Journal of Hospital Medicine

Volumn 7, Issue SUPPL. 1, 2012, Pages

  Snydman, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM CONTAMINATION; BLOODSTREAM INFECTION; CASE REPORT; CATHETER INFECTION; CHILL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DIVERTICULITIS; DRUG ABUSE; DRUG EXPOSURE; DYSPNEA; ELECTROCARDIOGRAM; EMPIRICAL RESEARCH; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; FEVER; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFECTION; HEALTH CARE; HEALTH CARE COST; HEART FUNCTION; HEART RATE; HOSPITAL; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KLEBSIELLA INFECTION; LEGIONNAIRE DISEASE; LEUKOCYTE COUNT; LIVER FUNCTION; LUNG INFECTION; MALE; MEDICAL EXPERT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; OXYGEN SATURATION; PATIENT CARE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEUS INFECTION; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SEPSIS; SERRATIA INFECTION; STREPTOCOCCUS INFECTION; THERAPY DELAY; URINARY TRACT INFECTION; VEIN PUNCTURE; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION; AGED; BACTERIAL PNEUMONIA; CROSS INFECTION; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; TIME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EMPIRICAL RESEARCH; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TIME FACTORS;

EID: 84855329216     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.980     Document Type: Review

References (93)

1. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect. 2008; 14( suppl 3): 15-21.
2. Kollef MH Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31( suppl 4): S131-S138.
3. Niederman MS. Treatment options for nosocomial pneumonia due to MRSA. J Infect. 2009; 59( suppl 1): S25-S31.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115: 462-474.
5. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 2001; 27: 355-362.
6. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother. 2008; 61: 436-441.
7. Mueller EW, Hanes SD, Croce MA, Wood GC, Boucher BA, Fabian TC. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma. 2005; 58: 94-101.
8. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008; 134: 281-287.
9. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest. 2008; 134: 963-968.
10. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008; 23: 91-100.
11. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007; 35: 379-385; quiz 386.
12. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006; 27: 158-164.
13. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997; 111: 676-685.
14. Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect. 2007; 65: 361-367.
15. Gomez J, Garcia-Vazquez E, Banos R, et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis. 2007; 26: 239-245.
16. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003; 115: 529-535.
17. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118: 146-155.
18. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005; 49: 760-766.
19. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998; 244: 379-386.
20. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005; 49: 1306-1311.
21. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39: 31-37.
22. Rodriguez-Bano J, Millan AB, Dominguez MA, et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Infect. 2009; 58: 131-137.
23. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46: 193-200.
24. Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect. 2011; Jan 13:1-10.
25. Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt). 2008; 9: 335-347.
26. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004; 23: 682-687.
27. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996; 23: 486-494.
28. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg. 1991; 214: 543-549.
29. Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 2005; 60: 438-443.
30. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007; 35: 1888-1895.
31. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28: 873-876.
32. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007; 60: 855-863.
33. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med. 2000; 160: 1001-1004.
34. Sostarich AM, Zolldann D, Haefner H, Luetticken R, Schulze-Roebecke R, Lemmen SW. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay. Infection. 2008; 36: 31-35.
35. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008; 52: 813-821.
36. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009; 37: 1463-1469.
37. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010; 54: 3717-3722.
38. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002; 122: 262-268.
39. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003; 36: 1418-1423.
40. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008; 47( suppl 1): S3-S13.
41. Lipman J, Boots R. A new paradigm for treating infections: "go hard and go home." Crit Care Resusc. 2009; 11: 276-281.
42. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis. 2006; 42( suppl 2): S72-S81.
43. Livermore DM, Pearson A. Antibiotic resistance: location, location, location. Clin Microbiol Infect. 2007; 13( suppl 2): 7-16.
44. Babcock HM, Zack JE, Garrison T, Trovillion E, Kollef MH, Fraser VJ. Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect Control Hosp Epidemiol. 2003; 24: 853-858.
45. Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma. 2000; 49: 638-645; discussion 645-646.
46. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 1999; 160: 608-613.
47. Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
48. Engel LS. The dilemma of multidrug-resistant gram-negative bacteria. Am J Med Sci. 2010; 340: 232-237.
49. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002; 50: S226-S229.
50. Herring AR, Williamson JC. Principles of antimicrobial use in older adults. Clin Geriatr Med. 2007; 23: 481-497, v.
51. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009; 22: 352-358.
52. Weber DJ. Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. Int J Infect Dis. 2006; 10: S17-S24.
53. Archibald LK, Pallangyo K, Kazembe P, Reller LB. Blood culture contamination in Tanzania, Malawi, and the United States: a microbiological tale of three cities. J Clin Microbiol. 2006; 44: 4425-4429.
54. Alahmadi YM, Aldeyab MA, McElnay JC, et al. Clinical and economic impact of contaminated blood cultures within the hospital setting. J Hosp Infect. 2011; 77: 233-236.
55. Bates DW, Goldman L, Lee TH. Contaminant blood cultures and resource utilization. The true consequences of false-positive results. JAMA. 1991; 265: 365-369.
56. Everts RJ, Vinson EN, Adholla PO, Reller LB. Contamination of catheter-drawn blood cultures. J Clin Microbiol. 2001; 39: 3393-3394.
57. Falagas ME, Kazantzi MS, Bliziotis IA. Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. J Med Microbiol. 2008; 57: 1-8.
58. Shahar E, Wohl-Gottesman BS, Shenkman L. Contamination of blood cultures during venepuncture: fact or myth? Postgrad Med J. 1990; 66: 1053-1058.
59. Dellit TH, Owens RC, McGowan JEJr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177.
60. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med. 2010; 123: 631-637.
61. Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore). 2009; 88: 263-267.
62. McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, Scull JA, Martinelli LP. The value of infectious diseases specialists: non-patient care activities. Clin Infect Dis. 2008; 47: 1051-1063.
63. Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. Clin Infect Dis. 2003; 36: 1013-1017.
64. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation-a study of 521 patients in Germany. J Infect. 2009; 59: 232-239.
65. Kieninger AN, Lipsett PA. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am. 2009; 89: 439-461, ix.
66. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999; 27: 887-892.
67. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am. 2004; 18: 939-962.
68. Lujan M, Gallego M, Rello J. Healthcare-associated infections. A useful concept? Curr Opin Crit Care. 2009; 15: 419-424.
69. Bauer TT, Ferrer R, Angrill J, Schultze-Werninghaus G, Torres A. Ventilator-associated pneumonia: incidence, risk factors, and microbiology. Semin Respir Infect. 2000; 15: 272-279.
70. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998; 157: 531-539.
71. Gadani H, Vyas A, Kar AK. A study of ventilator-associated pneumonia: incidence, outcome, risk factors and measures to be taken for prevention. Indian J Anaesth. 2010; 54: 535-540.
72. Rello J, Ausina V, Ricart M, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med. 1994; 20: 193-198.
73. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009; 30: 102-115.
74. Fartoukh M, Maitre B, Honore S, Cerf C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med. 2003; 168: 173-179.
75. Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg. 1992; 127: 83-89.
76. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50: 133-164.
77. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am. 2009; 89: 421-437, ix.
78. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents. 2009; 34: 585-588.
79. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2010; 54: 3031-3034.
80. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29: 996-1011.
81. Weber DJ, Rutala WA. Central line-associated bloodstream infections: prevention and management. Infect Dis Clin North Am. 2011; 25: 77-102.
82. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39: 309-317.
83. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32: 470-485.
84. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother. 2009; 64: 169-174.
85. Rosenthal VD, Maki DG, Jamulitrat S, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control. 2010; 38: 95-104, e102.
86. Klevens RM, Edwards JR, Gaynes RP. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis. 2008; 47: 927-930.
87. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA. 2009; 301: 727-736.
88. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52: 285-292.
89. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010; 6: 1017-1031.
90. Scheetz MH, Hoffman M, Bolon MK, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009; 64: 311-319.
91. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98.
92. Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet. 2009; 48: 517-528.
93. Lodise TPJr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44: 357-363.